Trace Neuroscience
About Trace Neuroscience
Trace Neuroscience is developing antisense oligonucleotides to restore UNC13A protein function, which is critical for synaptic communication between nerves and muscle cells in individuals with amyotrophic lateral sclerosis (ALS). By correcting the splicing of UNC13A mRNA, the company aims to improve muscle function and extend the lives of the approximately 30,000 people in the U.S. living with this debilitating disease.
```xml <problem> Amyotrophic lateral sclerosis (ALS) is characterized by impaired communication between nerves and muscle cells due to synaptic dysfunction. In approximately 97% of ALS patients, the protein TDP-43 mislocalizes, leading to improper splicing of UNC13A mRNA and insufficient production of the UNC13A protein. This deficiency disrupts nerve and muscle function, contributing to the progression of the disease. </problem> <solution> Trace Neuroscience is developing antisense oligonucleotides (ASOs) designed to restore UNC13A protein function in individuals with ALS. The company's therapeutic approach targets the UNC13A mRNA to correct splicing, thereby increasing UNC13A protein production. By restoring UNC13A levels, Trace Neuroscience aims to re-establish healthy communication between nerves and muscle cells, improve muscle function, and ultimately extend the lives of people living with ALS. The ASO is designed to bind directly to the UNC13A mRNA and ensure proper splicing. </solution> <features> - Antisense oligonucleotide (ASO) therapeutic approach - Targets UNC13A mRNA to correct splicing errors - Designed to restore UNC13A protein levels in nerve and muscle cells - Aims to re-establish healthy synaptic communication - Potential applicability to other neurodegenerative diseases beyond ALS, such as frontotemporal dementia and Alzheimer’s </features> <target_audience> The primary target audience is individuals diagnosed with ALS, particularly those with TDP-43 mislocalization, as well as clinicians and researchers focused on neurodegenerative diseases. </target_audience> ```
What does Trace Neuroscience do?
Trace Neuroscience is developing antisense oligonucleotides to restore UNC13A protein function, which is critical for synaptic communication between nerves and muscle cells in individuals with amyotrophic lateral sclerosis (ALS). By correcting the splicing of UNC13A mRNA, the company aims to improve muscle function and extend the lives of the approximately 30,000 people in the U.S. living with this debilitating disease.
Where is Trace Neuroscience located?
Trace Neuroscience is based in San Francisco, United States.
When was Trace Neuroscience founded?
Trace Neuroscience was founded in 2024.
How much funding has Trace Neuroscience raised?
Trace Neuroscience has raised 101000000.
- Location
- San Francisco, United States
- Founded
- 2024
- Funding
- 101000000
- Employees
- 15 employees
- Major Investors
- Third Rock Ventures